,4 The anti-PD-L1 monoclonal antibody atezolizumab also improves survival in the first-line setting, either as monotherapy for patients with PD-L1 expression on immune or tumor cells ≥50%, or in combination with platinum-based chemotherapy5,6 with or without the anti-angiogenic agent bevacizumab.7 The gene discussed is CD274; the disease is neoplasm.